Logo image of MRSN

MERSANA THERAPEUTICS INC (MRSN) Stock Fundamental Analysis

NASDAQ:MRSN - Nasdaq - US59045L1061 - Common Stock - Currency: USD

0.3977  0 (-0.58%)

After market: 0.3878 -0.01 (-2.49%)

Fundamental Rating

2

Overall MRSN gets a fundamental rating of 2 out of 10. We evaluated MRSN against 566 industry peers in the Biotechnology industry. MRSN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, MRSN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MRSN has reported negative net income.
In the past year MRSN has reported a negative cash flow from operations.
In the past 5 years MRSN always reported negative net income.
MRSN had a negative operating cash flow in each of the past 5 years.
MRSN Yearly Net Income VS EBIT VS OCF VS FCFMRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

MRSN has a Return On Assets (-47.83%) which is in line with its industry peers.
Industry RankSector Rank
ROA -47.83%
ROE N/A
ROIC N/A
ROA(3y)-61.62%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRSN Yearly ROA, ROE, ROICMRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRSN Yearly Profit, Operating, Gross MarginsMRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K

More info and screens

2

2. Health

2.1 Basic Checks

MRSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRSN has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MRSN has more shares outstanding
Compared to 1 year ago, MRSN has a worse debt to assets ratio.
MRSN Yearly Shares OutstandingMRSN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MRSN Yearly Total Debt VS Total AssetsMRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -9.25, we must say that MRSN is in the distress zone and has some risk of bankruptcy.
MRSN's Altman-Z score of -9.25 is on the low side compared to the rest of the industry. MRSN is outperformed by 72.44% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.25
ROIC/WACCN/A
WACC11.92%
MRSN Yearly LT Debt VS Equity VS FCFMRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.19 indicates that MRSN has no problem at all paying its short term obligations.
MRSN's Current ratio of 2.19 is on the low side compared to the rest of the industry. MRSN is outperformed by 73.67% of its industry peers.
MRSN has a Quick Ratio of 2.19. This indicates that MRSN is financially healthy and has no problem in meeting its short term obligations.
MRSN has a Quick ratio of 2.19. This is in the lower half of the industry: MRSN underperforms 72.08% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
MRSN Yearly Current Assets VS Current LiabilitesMRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.56% over the past year.
The Revenue has grown by 9.89% in the past year. This is quite good.
MRSN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.78% yearly.
EPS 1Y (TTM)60.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)9.89%
Revenue growth 3Y904.13%
Revenue growth 5Y-0.78%
Sales Q2Q%52.89%

3.2 Future

The Earnings Per Share is expected to grow by 32.57% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 62.11% on average over the next years. This is a very strong growth
EPS Next Y-29.84%
EPS Next 2Y-8.93%
EPS Next 3Y-10.88%
EPS Next 5Y32.57%
Revenue Next Year-3.73%
Revenue Next 2Y-10.77%
Revenue Next 3Y-12.88%
Revenue Next 5Y62.11%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRSN Yearly Revenue VS EstimatesMRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
MRSN Yearly EPS VS EstimatesMRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRSN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRSN Price Earnings VS Forward Price EarningsMRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRSN Per share dataMRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

MRSN's earnings are expected to decrease with -10.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.93%
EPS Next 3Y-10.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRSN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERSANA THERAPEUTICS INC

NASDAQ:MRSN (5/2/2025, 8:11:11 PM)

After market: 0.3878 -0.01 (-2.49%)

0.3977

0 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners92.18%
Inst Owner Change0.04%
Ins Owners1.54%
Ins Owner Change0.3%
Market Cap49.57M
Analysts86.67
Price Target4.93 (1139.63%)
Short Float %8.2%
Short Ratio3.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.38%
Min EPS beat(2)33.06%
Max EPS beat(2)49.71%
EPS beat(4)3
Avg EPS beat(4)20.43%
Min EPS beat(4)-14.37%
Max EPS beat(4)49.71%
EPS beat(8)5
Avg EPS beat(8)11.47%
EPS beat(12)6
Avg EPS beat(12)-45.29%
EPS beat(16)7
Avg EPS beat(16)-36.87%
Revenue beat(2)2
Avg Revenue beat(2)86.47%
Min Revenue beat(2)64.02%
Max Revenue beat(2)108.93%
Revenue beat(4)3
Avg Revenue beat(4)26.34%
Min Revenue beat(4)-74.22%
Max Revenue beat(4)108.93%
Revenue beat(8)3
Avg Revenue beat(8)-2.56%
Revenue beat(12)4
Avg Revenue beat(12)-7.97%
Revenue beat(16)5
Avg Revenue beat(16)-13.06%
PT rev (1m)5.07%
PT rev (3m)-25.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)15.07%
Revenue NY rev (1m)21.36%
Revenue NY rev (3m)7.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.32
BVpS-0.08
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.83%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.62%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.11%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -9.25
F-Score4
WACC11.92%
ROIC/WACCN/A
Cap/Depr(3y)129.19%
Cap/Depr(5y)101.94%
Cap/Sales(3y)4.83%
Cap/Sales(5y)339.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y-29.84%
EPS Next 2Y-8.93%
EPS Next 3Y-10.88%
EPS Next 5Y32.57%
Revenue 1Y (TTM)9.89%
Revenue growth 3Y904.13%
Revenue growth 5Y-0.78%
Sales Q2Q%52.89%
Revenue Next Year-3.73%
Revenue Next 2Y-10.77%
Revenue Next 3Y-12.88%
Revenue Next 5Y62.11%
EBIT growth 1Y57.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.24%
OCF growth 3YN/A
OCF growth 5YN/A